Efficacy of Low-Dose Methotrexate in Rheumatoid Arthritis

New England Journal of Medicine

Volumn 312, Issue 13, 1985, Pages 818-822

  Weinblatt, Michael E ^a   Coblyn, Jonathan S ^a   Fox, David A ^a   Fraser, Patricia A ^a   Holdsworth, Donald E ^a   Glass, David N ^a   Trentham, David E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; GOLD SALT; HYDROXYCHLOROQUINE; METHOTREXATE; PENICILLAMINE; PLACEBO; PREDNISONE;

ARTHROPATHY; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE; DRUG EFFICACY; DRUG THERAPY; HUMAN; HUMAN EXPERIMENT; JOINT; METHODOLOGY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; THERAPY;

EID: 0021923633     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198503283121303     Document Type: Article

References (25)

1. Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951; 221: 176–82.
2. Willkens RF, Watson MA, Paxson CS. Low dose pulse methotrexate therapy in rheumatoid arthritis. J Rheumatol 1980; 7: 501–5.
3. Steinsson K, Weinstein A, Korn J, Abeles M. Low dose methotrexate in rheumatoid arthritis. J Rheumatol 1982; 9: 860–6.
4. Brahn E, Helfgott SM, Belli JA, et al. Total lymphoid irradiation therapy in refractory rheumatoid arthritis: fifteen- to forty-month follow-up. Arthritis Rheum 1984; 27: 481–8.
5. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949; 140: 659–62.
6. Williams HJ, Ward JR, Reading JC, et al. Low-dose D-penicillamine therapy in rheumatoid arthritis: a controlled, double-blind clinical trial. Arthritis Rheum 1983; 26: 581–92.
7. Ward JR. Williams HJ, Egger MJ, et al. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1983; 26: 1303–15.
8. Pinals RS, Masi AT, Larsen RA, et al. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24: 1308–15.
9. Miller ML, Fraser PA, Jackson JM, et al. Inherited predisposition to iridocyclitis in juvenile rheumatoid arthritis: selectivity among HLA-DR5 haplotypes. Proc Natl Acad Sci USA 1984; 81: 3539–42.
10. Trentham DE, Belli JA, Anderson RJ, et al. Clinical and immunologic effects of fractionated total lymphoid irradiation in refractory rheumatoid arthritis. N Engl J Med 1981; 305: 976–82.
11. Nadler LM, Stashenko P, Hardy R, Pesando JM, Yunis EJ, Schlossman SF. Monoclonal antibodies defining serologically distinct HLA-D/DR related Ia-like antigens in man. Hum Immunol 1981; 2: 77–90.
12. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980; 125: 1678–85.
13. Todd RF III, Nadler LM, Schlossman SF. Antigens on human nionocytes identified by monoclonal antibodies. J Immunol 1981; 126: 1435–42.
14. Meuer SC, Hussey RE, Fabbi M, et al. An alternative pathway of T-cell activation: a functional role for the 50 kd T11 sheep crythrocyte receptor protein. Cell 1984; 36: 897–906.
15. Fox DA, Hussey RE, Fitzgerald KA, et al. Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody. J Immunol 1984; 133: 1250–6.
16. Snedecor GW, Cochran WG. Statistical methods. 6th ed. Ames, Iowa: Iowa State University Press, 1967:419–46.
17. Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD. Methotrexate guidelines — revised. J Am Acad Dermatol 1982; 6: 145–55.
18. Sostman HD, Matthay RA, Putman CE, Smith GJW. Methotrexate-induced pneumonitis. Medicine (Baltimore) 1976; 55: 371–88.
19. Cannon GW, Ward JR, Clegg DO, Samuelson CO Jr, Abbott TM. Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis. Arthritis Rheum 1983; 26: 1269–74.
20. Roenigk HH Jr, Bergfeld WF, St. Jacques R, Owens FJ, Hawk WA. Hepatotoxicity of methotrexate in the treatment of psoriasis. Arch Dermatol 1971; 103: 250–61.
21. Haraoui B, Wilder RL, Malone DG, Allen JB, Katona IM, Wahl SM. Immune function in severe, active rheumatoid arthritis: a relationship between peripheral blood mononuclear cell proliferation to soluble antigens and mononuclear cell subset profiles. J Immunol 1984; 133: 697–701.
22. Wahl SM, Wilder RL, Katona IM, et al. Leukapheresis in rheumatoid arthritis: association of clinical improvement with reversal of anergy. Arthritis Rheum 1983; 26: 1076–84.
23. Panayi GS, Wooley P, Batchelor JR. Genetic basis of rheumatoid disease: HLA antigens, disease manifestations, and toxic reactions to drugs. Br Med J 1978; 2: 1326–8.
24. Young A, Jaraquemada D, Awad J, et al. Association of HLA-DR4/Dw4 and DR2/Dw2 with radiologic changes in a small prospective study of patients with rheumatoid arthritis: preferential relationship with HLA-Dw rather than HLA-DR specificities. Arthritis Rheum 1984; 27: 20–5.
25. Ward JR. A prospective randomized controlled trial of low dose pulse methotrexate in rheumatoid arthritis. Arthritis Rheum 1984; 27: (4: Suppl):S40. abstract.